Overview

Treatment for Presumed Ocular Histoplasmosis

Status:
Unknown status

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

John Kitchens, MD

Treatments:

Aflibercept